Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 4, 2004, Pages 98-103

  Lorusso, D ^b   Ferrandina, G ^a   Lo Voi, R ^a   Fagotti, A ^a   Scambia, Giovanni ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Ovarian cancer; Pegylated Liposomal Doxorubin

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; DOXORUBICIN; LIPOSOME; MACROGOL; PACLITAXEL; PLATINUM DERIVATIVE; POLYMER; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; FEBRILE NEUTROPENIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; KAPOSI SARCOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SEPSIS; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 11244279775     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.supplement-1.98     Document Type: Conference Paper

References (28)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
3. Ozols RF, Rubin SC, Thomas G, et al. Epithelial ovarian cancer, in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynaecologic Oncology, Philadelphia, PA, Lippincott-Raven, 1997; 1514-39.
4. Kavanagh J, Tresukolos D, Edwards C, et al. Carboplatin reintroduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584-88.
5. Bookman M, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-52.
6. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second line therapy for platinum-resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-10.
7. Shapiro JD, Millaward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.
8. Vermorken JB, Harper PG, Buyse M. The role of anthracyclines in epithelial ovarian cancer. Ann Oncol 1999; 10 (Supp 1): S43-50.
9. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32.
10. Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 1991; 9: 1668-74.
11. Gordon AN, Granai CO, Rose P, et al. Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-100.
12. Gabizon A, Catne R, Uziely B, et al. Prolongation of the circulation tissue and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol coated liposomes. Cancer Res 1994; 54: 987-992.
13. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777-85.
14. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use for solid tumors. Drugs 1997; 54(suppl 4): 15-21.
15. Johnston SR, Gore ME. Caelyx: phase II studies in ovarian cancer. Eur J Cancer 2001; 37(9): SS-S14.
16. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93.
17. 2) in platinum/paclitaxelrefractory ovarian and fallopian tube cancer and primary carcinoma of the peritoneum. Gynecol Oncol 2000; 78: 369-72.
18. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
19. Hansen SW, Tuxen MK, Sessa C et al. Gemcitabine in the treatment of ovarian cancer. Ann Oncol 1999; 10(S1): 51-53.
20. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002; 29(S1): 9-10.
21. Zoli W, Ricotti L, Barzanti F, et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 1999; 80: 413-416.
22. Chow KU, Ries J, Weidmann E, et al. Induction of apoptosis using 2,2difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Ann Hematol 2000; 79: 485-492.
23. D'Agostino G, Ferrandina G, Garganese G, et al. Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology 2002; 62: 110-114.
24. Mathe G, Reizenstein P. Ethics and errors of clinical trials and the role and place of trial. Drugs Exp Clin Res: 1986; 12(1-3): 1-9.
25. D'Agostino G, Ferrandina G, Ludovisi M et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer 2003; 89: 1180-84.
26. Lorusso D, Naldini A, Testa A et al. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients: may a new treatment schedule improve toxicity profile? Oncology, 2004; in press.
27. Hansen SW. Gemcitabine, platinum and Paclitaxel regimens in patients with advanced ovarian carcinoma. Sem Oncol 2002; 29 (Suppl 1): 17-19.
28. Israel VP, Garcia AA, Roman L, et al. Phase II study of liposomal doxorubicin in advanced gynaecological cancer. Gynecol Oncol 2000; 78: 143-7.